Palovarotene (Figure 4), a retinoic acid receptor and selective agonist for EXT1/EXT2-CDG, has already shown clinical safety for fibrodysplasia ossificans progressiva and emphysema [98,99]. The gene discussed is EXT1; the disease is fibrodysplasia ossificans progressiva.